• Explore /
  • Poster
  • / Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.

Abstract Video & Slides Poster

Authors

Jennifer Diamond

Jennifer Robinson Diamond

University of Colorado Anschutz Medical Campus, Aurora, CO

Jennifer Robinson Diamond , Jason Timothy Henry , Gerald Steven Falchook , Anthony J. Olszanski , Harshabad Singh , E. Jane Leonard , Richard C. Gregory , Vicky A. Appleman , John Gibbs , Carole Harbison , Cong Li , Jessica M. Sapiro , Tomoki Yoneyama , Alexander A Parent , Vincent Chung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT05070247

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2690)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2690

Abstract #

TPS2690

Poster Bd #

333a

Abstract Disclosures

Similar Posters

First Author: Gerald Steven Falchook

First Author: Sarina Anne Piha-Paul

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

First Author: David Hsieh

First Author: Philippe L. Bedard